Endocrine Abstracts

Introduction: US Food and Drug Administration (FDA) has recently approved bexagliflozin, a new SGLT2 inhibitor. We examined the outcomes and metabolic effects of Bexagliflozin across the published Randomised Controlled Trials (RCCTs)Methods: A comprehensive literature search was done to extract publications from Medline-PubMed and Cochrane library, since inception till January 20, 2023, then screened and reviewed by two independent reviewers. Data includ...